Mangoceuticals Reports 336% MoM Sales Growth for Injectable TRT Program, Cuts Customer Acquisition Costs by 54%
MGRX sits 46% above its 52-week low of $0.34 on elevated volume (2.2× avg).
Summary
Mangoceuticals announced strong initial sales for its new injectable TRT program, achieving 336% month-over-month growth and a 54% reduction in customer acquisition costs.
Key Events · Product Development and Regulatory · MGRX
-
Significant Sales Growth
The newly launched all-inclusive injectable Testosterone Replacement Therapy (TRT) treatment program experienced a 336% month-over-month sales increase since its mid-December launch.
-
Reduced Customer Acquisition Costs
Customer acquisition costs (CAC) for the TRT program were reduced by 54%, indicating improved marketing efficiency.
-
Strategic Focus on TRT
TRT is expected to be the primary growth driver, with plans to invest further in both injectable and oral formulations.
-
Telehealth Platform Expansion
The company aims to evolve its telehealth platform to offer a broader range of men's health and wellness solutions beyond specialized treatments.
Analysis · MGRX · Industrial Applications And Services
This 8-K filing highlights significant initial success for Mangoceuticals' newly launched injectable Testosterone Replacement Therapy (TRT) program. The reported 336% month-over-month sales growth and 54% reduction in customer acquisition costs are substantial for a company of this size, especially given its recent Nasdaq deficiency notice. This positive operational momentum could be crucial for the company's efforts to address its listing requirements and improve its financial standing. The focus on TRT as a primary growth driver, coupled with plans to expand its telehealth platform for men's health, indicates a clear strategic direction that is showing early signs of traction. Investors should monitor if this growth is sustainable and translates into improved financial results and a resolution to the Nasdaq bid price deficiency.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MGRX was trading at $0.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.8M. The 52-week trading range was $0.34 to $6.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.